What is the price of entrectinib after medical insurance reimbursement in 2025?

Entrectinib is a targeted therapy drug designed for patients with tumors carrying specific gene fusion mutations. It is especially suitable for patients with NTRK gene fusion-positive solid tumors and patients with ROS1-positive non-small cell lung cancer (NSCLC). Its mechanism of action is to inhibit the tyrosine kinase activity that specific fusion proteins in tumor cells rely on, blocking signaling pathways, thereby delaying the progression and spread of tumors. This "gene-driven" rather than "organ-driven" treatment approach makes entrectinib an important representative of a class of tissue-independent drugs, providing more targeted treatment options for patients with rare mutation cancers.

In the Chinese market, entrectinib has been approved for marketing by the State Food and Drug Administration in 2021 and successfully entered the National Reimbursement List in 2023, marking its further solidification of its position in the field of precision tumor treatment in China. According to the relevant provisions of the medical insurance policy, patients who meet the indications for entrectinib can enjoy medical insurance reimbursement if they are confirmed by genetic testing to have NTRK or ROS1 fusion mutations and meet the conditions prescribed by a doctor. This policy of medical insurance coverage has greatly reduced the financial burden on patients and enabled more patients with indications to have access to innovative treatments.

In terms of actual market prices, the common dosage forms of entrectinib are100mg capsules (30 capsules/box) and 200mg capsules (90 capsules/box). The price of each box before reimbursement is approximately RMB 20,000. However, the actual out-of-pocket amount of patients after medical insurance reimbursement varies depending on the region, medical insurance type and reimbursement ratio, which is a great financial relief for long-term users.

In the future, as medical insurance policies are further optimized and more targeted drugs are included in the catalog, entrectinib may bring clinical value in more indications and provide more hope for patients with gene-driven tumors.

Reference materials:https://www.roche.com/products/rozlytrek